Form 4: Cidara COO Sells Shares After Option Exercise

Cidara Therapeutics' COO & CLO, Shane Ward, reported exercising stock options and subsequently selling a portion of his common stock holdings.

Summary

• Shane Ward, COO & CLO of Cidara Therapeutics, Inc. (CDTX), reported multiple transactions on December 10, 2025.
• Ward exercised employee stock options to acquire a total of 9,959 shares of common stock (3,500 shares at $16.654 and 6,459 shares at $20.2).
• Concurrently, 15,041 shares were withheld for taxes related to RSU vesting at a price of $219.6 per share.
• Ward also sold 9,959 shares of common stock at an average price of $220.077 per share.
• Following these transactions, Ward's direct beneficial ownership of common stock is 25,033 shares.
• The reported share numbers reflect a 1-for-20 reverse stock split effected on April 24, 2024.
• Ward acquired 400 shares through the Employee Stock Purchase Plan (ESPP) on May 20, 2025, and November 20, 2025.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (option exercises, tax-related dispositions, and a sale). While a sale by an executive can sometimes be viewed negatively, it's often part of a pre-arranged plan or for personal financial management, balancing out the positive signal of option exercises.

Positives

• Management exercised stock options, indicating a realization of value from prior grants.

Negatives

• A significant number of shares (9,959) were sold by a key executive, which could be perceived negatively by investors.
• 15,041 shares were withheld for taxes, representing a substantial disposition of shares.

Future Outlook

The filing does not contain forward-looking statements or guidance, as it is a transactional report of insider stock activity.

Industry Context

This Form 4 filing details routine insider transactions (option exercises, tax-related dispositions, and open market sales) for a biotechnology company. Such transactions are common for executives managing their equity compensation and personal finances. The 1-for-20 reverse stock split mentioned indicates a corporate action likely taken to meet listing requirements or improve stock perception, a trend sometimes seen in smaller cap biotech firms.

Comparison to Industry Standards

• Insider transactions like option exercises and subsequent sales are standard practice across industries, particularly in biotechnology where equity compensation is a significant component of executive pay.
• The sale of shares after exercising options is a common strategy for executives to realize gains and manage personal liquidity or diversification.
• The reverse stock split is a corporate action that can be compared to similar actions by other companies in the biotech sector facing similar stock price challenges, such as those undertaken by smaller pharmaceutical or life sciences companies aiming to maintain exchange listing compliance or attract institutional investors.

Stakeholder Impact

• Shareholders: May observe a slight increase in shares available on the market due to the sale, and potentially interpret the executive's sale as a signal, though often it's for personal financial planning.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including option exercises and subsequent sales, by a key executive. While the sale of shares by an insider can sometimes be a negative signal, the exercise of options indicates a realization of value from prior grants. Without additional context on the company's financial performance, strategic outlook, or the executive's specific financial planning, these transactions alone do not provide a strong basis for a 'buy' or 'sell' recommendation. Investors should 'hold' and consider these transactions as part of a broader analysis of Cidara Therapeutics' fundamentals and market position.

Keywords

Cidara Therapeutics, CDTX, Shane Ward, Insider Trading, Stock Option Exercise, Share Sale, Form 4, Beneficial Ownership, COO, CLO